AstraZeneca Plc is to open a new research site in Cambridge, Massachusetts, US, as it consolidates its July 2021 acquisition of Alexion Pharmaceuticals Inc, a developer of drugs for rare diseases. AstraZeneca paid $39 billion for the US company which has marketed products as well as more than 20 projects in development.
